Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2008
06/04/2008CN100391454C Preparation of hydrobromic acid dextro methaphen and beta cyclodeatrin compounding object
06/04/2008CN100391453C Cremaster ketone preparation
06/04/2008CN100391452C Red sage root preparation for injection and its preparation method
06/04/2008CN100391451C Application of cantharidin derivative in preparation of antitumour medicine
06/04/2008CN100391450C Compound medicine composition and its preparation and use
06/04/2008CN100391449C Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
06/04/2008CN100391448C Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
06/04/2008CN100391447C Freeze dried powder injection of coenzyme Q10 and its preparation process
06/04/2008CN100391446C Method of rearing and feeds
06/04/2008CN100391441C Matrine elaioplast drop ball and its preparation method
06/04/2008CN100391440C Formulation based on heparin, glycosaminogl ycan or heparinoid, use of the formulation and the formulation base
06/04/2008CN100391439C Immunopotentiators
06/04/2008CN100391438C Process for making aqueous coated beadlets
06/04/2008CN100391433C Carotenoid composition and method for protecting skin
06/04/2008CN100391432C Skin depigmenting compositions comprising adapalene and at least one depigmenting active agent
06/04/2008CN100391430C Health care towel for health of feet
06/04/2008CN100391354C Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis
06/03/2008USRE40360 Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide
06/03/2008USH2218 Producing glucosamine by acid hydrolysis of fermented microbial biomass
06/03/2008US7381848 2-methoxyestradiol in a biodegradable polymer; administered for treatment of tumors
06/03/2008US7381841 Cardiovascular disorders; antiischemic agenst
06/03/2008US7381840 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists
06/03/2008US7381826 Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
06/03/2008US7381825 Antiinflammatory agents; skin disorders; inflammatory bowel disorders
06/03/2008US7381824 Quinoline derivatives
06/03/2008US7381822 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process
06/03/2008US7381820 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside
06/03/2008US7381813 A modified estrogen receptor alpha ligand binding domain containing an amino acid modification in region 1, at region 2, or atleast one amino acid modifiation in both of regions, and these domain interacts with a nonendogenous ligand
06/03/2008US7381808 Method and nucleic acids for the differentiation of prostate tumors
06/03/2008US7381807 Of given nucleotide sequence; encapsulated in slow release delivery vehicle; includes viral or bacterial antigen; increases cell proliferation, differentiation, cytokine and antibody production for lymphocytes
06/03/2008US7381751 Mixture of silicone resin with chelate compound, pigemnt and lubricant; molding
06/03/2008US7381750 Amino-phenoxymethyl-benzamide opioid receptor antagonists
06/03/2008US7381749 Sulfonamides as inhibitors of histone deacetylase for the treatment of disease
06/03/2008US7381748 Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase
06/03/2008US7381747 3-Aminomethyl-5-methyl-octanoic acid; antidepressant and anxiolytic agent; obsessive compulsive disorder (OCD), agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia; not addictive
06/03/2008US7381745 Central nervous system disorders; psychological disorders
06/03/2008US7381744 inhibit intra-organellar acidification of intracellular organelles; activity in the plasma membranes of kidney intercalated cells, osteoclasts and sperm cells; urinary acidification, bone resorption, or the acrosomal acid secretion required for fertility, adjuncts to cancer therapy
06/03/2008US7381743 Macrocycles for the treatment of cancer
06/03/2008US7381742 Optically active polymaleimide derivatives and process for their production
06/03/2008US7381741 In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors
06/03/2008US7381740 Melatonin analogue prodrugs
06/03/2008US7381739 Antiserotonine agents; central nervous system disorders; Alzheimer's disease; Parkinson's disease; Huntington's disease; sleep disorders
06/03/2008US7381738 Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
06/03/2008US7381737 5-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid; cell-cell and cell-substrate adhesion inhibitor; industrial scale; cyclization with condensed methylene precursor compound and glycine; separation of enantiomeric mixture
06/03/2008US7381736 N-(4-{2-[[3-Bromo-4-(difluoro-phosphono-methyl)-benzyl]-(3 ,4-dichloro-phenyl)-amino]-thiazol-4-yl}-phenyl)-oxalamic acid; antidiabetic, hypotensive agent; ischemia, kidney failure, atherosclerosis, metabolic syndrome, insulin resistance, leptin resistance, obesity, neurodegenerative diseases
06/03/2008US7381735 Ultrashort-acting opioids for transdermal application
06/03/2008US7381734 Serine protease inhibitors
06/03/2008US7381733 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
06/03/2008US7381732 inhibitors of trypsin-like serine proteases; anticoagulant agents to treat thromboembolic disorders;
06/03/2008US7381731 Pharmaceutical composition comprising citrulline
06/03/2008US7381730 Bone disorders, cardiovascular diseases, anticholesterol agents, hypertriglyceridemia, vasomotor disorders, urogenital disorders, prostatic hypertrophy, endometrial hyperplasia, anticarcinogenic agents; CNS disorders; side effect reduced
06/03/2008US7381729 Gastrointestinal fluid solubility; adenosine-1 receptor agonist; hypertension, congestive heart failure, renal failure
06/03/2008US7381728 growth hormone secretagogue receptors agonists; N-[3-(cis-3,5-Dimethyl-1-piperazinyl)-4-(methyloxy)phenyl]-5-(2-pyridinyl)-2-thiophenesulfonamide; synthesis through the coupling of the piperazine derivatives with sulfonylhalides or pentafluorophenyloxy protected derivatives, or through interconversion
06/03/2008US7381727 Pyrrole derivatives, their preparation and their therapeutic use
06/03/2008US7381726 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
06/03/2008US7381725 Pyridazine derivatives as ligands for GABA receptors
06/03/2008US7381724 6(5-chloro-2-pyridyl-)-5-[4-methyl-1-piperazinyl]carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine for tranquilizers or hypnotics
06/03/2008US7381723 Antiserotonine agents; stroke, brain disorders;trauma; Alzheimer's disease; neurodegenerative disease; schizophrenia; psychological disorders; anxiolytic agents; controlling stresses; eating disorders; sleep disorders; sexual disorders
06/03/2008US7381722 poly (ADP-ribose) synthetase inhibitors; synergistic; indeno[1,2-c]isoquinoline derivatives; inflammatory disease, a reperfusion injury, diabetes or its complications, reoxygenation injury resulting from organ transplantation, an ischemic condition, Parkinson's disease, renal failure, a vascular disease
06/03/2008US7381721 Substituted piperidine compounds
06/03/2008US7381720 Tumor suppression agents with reduced side effects; anticancer; antibacterial and antiviral
06/03/2008US7381719 To treat obesity and Related Diseases; oral bioavailablility, oral administration; inhibition of orexigenic effects; side effects reduction; weight loss while maintaining or minimizing the loss of lean muscle mass; 6-[4-(2-Benzylamino-ethyl)-phenoxy]-nicotinamide
06/03/2008US7381718 new process for the preparation of a key intermediate
06/03/2008US7381717 Anti-HIV agents with dual sites of action
06/03/2008US7381715 Antimicrobial solid surface materials containing chitosan-metal complexes
06/03/2008US7381714 A1 adenosine receptor agonists
06/03/2008US7381713 Treatment of cancer by reduction of intracellular energy and pyrimidines
06/03/2008US7381710 Nucleic acid comprising a sequence encoding promyelocytic leukemia retinoic acid receptor alpha and a non-immunosuppressive inducer of tumor cell apoptosis which is arsenic; all-trans, 9-cis or 13-cis retinoic acid; or 4 allopurinol-l-ribonucleoside
06/03/2008US7381709 Method of expressing foreign gene in kidney
06/03/2008US7381560 Administering a chimeric anti-CD20 antibody; hybridomas; monoclonal antibodies
06/03/2008US7381558 Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
06/03/2008US7381537 Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
06/03/2008US7381526 Assays for drug discovery based on microcompetition with a foreign polynucleotide
06/03/2008US7381521 Anti-pathogenic composition useful in blood preservation
06/03/2008US7381434 Nut extract having different alkaloid profile; reduced level of carcinogens; supercritical CO2 extraction; maintaining nutraceutical effects; rapidly dissolving tablets
06/03/2008US7381428 Stabilized lanthanum carbonate compositions
06/03/2008US7381426 Therapy for bone disorders
06/03/2008US7381424 Hydrostatic delivery system for controlled delivery of agent
06/03/2008US7381419 Medical composition kit for treating lesioned abnormal tissue
06/03/2008US7381416 2-Substituted-4-(methylseleno)- or 4-(methylmono- or dioxoseleno)buttyric acid derivatives, e.g., 2-hydroxy-4-methylselenobutyric acid and dicyclohexylammonium L-2-hydroxy-4-methylselenobutyrate;
06/03/2008US7381411 Preventing influenza virus cell binding; schizophrenia; diagnosing chronic viral disease associated with cancer development
06/03/2008US7381404 Treatment for dry macular degeneration
06/03/2008US7381402 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
06/03/2008CA2536069C Use of green porphyrins in ocular diagnosis and therapy
06/03/2008CA2501587C Solid preparation having phase containing insulin sensitizer and another active ingredient uniformly mixed
06/03/2008CA2467964C Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/03/2008CA2435954C Preparation of non-crystalline atorvastatin calcium
06/03/2008CA2401711C Cyclic amide derivatives
06/03/2008CA2389360C Urea derivatives as anti-inflammatory agents
06/03/2008CA2382294C Use of docetaxel for treating hepatocellular carcinoma
06/03/2008CA2368186C Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
06/03/2008CA2350430C Method and apparatus for liposome production
06/03/2008CA2339934C Medicine for multiple sclerosis
06/03/2008CA2339628C Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
06/03/2008CA2335560C New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
06/03/2008CA2335065C Pharmaceutical formulations for aerosols with two or more active substances
06/03/2008CA2326356C Oral liquid antidepressant solution
06/03/2008CA2313024C Pharmaceutical compositions containing an omega-3 fatty acid oil
06/03/2008CA2305760C Inhibitors of nucleoside metabolism
06/03/2008CA2298820C The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives